
What is claimed is:


1. A compound of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein:

R^{1a} and R^{1b} each is independently hydrogen or methyl;

Q is methyl or  ;

L is selected from the group consisting of null, alkyl, -O-, and $-N(R^2)-$;

W is selected from the group consisting of null, alkyl, and –O-;

Y is selected from the group consisting of alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocyclyl, aryl, heteroaryl, $-OC(O)OR^3$, $-OC(O)R^4$, and $-NR^5R^6$, wherein said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocyclyl, aryl, and heteroaryl are optionally substituted with one or more groups independently selected from oxo, halogen, cyano, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocyclyl, aryl, and heteroaryl;

R^2, R^3, R^4 and R^5 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocyclyl, aryl, and heteroaryl, wherein said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocyclyl, aryl, and heteroaryl are optionally substituted with one or more groups independently selected from oxo, halogen, cyano, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocyclyl, aryl, and heteroaryl;

R^6 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, and -C(O)R^7; and

R^7 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, alkoxyl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocyclyl, aryl, and heteroaryl, wherein said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, alkoxyl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocyclyl, aryl, and heteroaryl are optionally substituted with one or more groups independently selected from oxo, halogen, cyano, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocyclyl, aryl, and heteroaryl,


with the provisos that when L is -O- or -N(R^2)-, W is not -O-, when W is -O-, Y is not -NR^5NR^6, and when W is -O-, Y is -C(O)OR^3 or -C(O)R^4.

2. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of claim 1, wherein R^{1a} and R^{1b} both are hydrogen.

3. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of claim 1, wherein R^{1a} and R^{1b} both are methyl.

4. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of claim 1, wherein R^{1a} is methyl and R^{1b} is hydrogen, or R^{1a} is hydrogen and R^{1b} is methyl.

5. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of any one of claims 1-4, wherein Q is methyl.

6. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of any one of claims 1-4, wherein Q is 

.

7. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of any one of claims 1-6, wherein L is –O-.

8. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of any one of claims 1-6, wherein L is $–N(R^2)-$, and R^2 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, and heteroalkynyl.

9. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of any one of claims 1-6, wherein L is $–N(R^2)-$, and R^2 is hydrogen or alkyl.

10. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of claim 8 or 9, wherein the alkyl is C_1-C_6 alkyl.

11. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of claim 10, wherein the C_1-C_6 alkyl is methyl.

12. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of any one of claims 1-11, wherein when L is null or alkyl, W is –O-.

13. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of any one of claims 1-6, wherein L is -O- and W is alkyl.

14. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of any one of claims 1-6, wherein L is $–N(R^2)-$, W is alkyl, and R^2 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, and heteroalkynyl.

15. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of any one of claims 1-6, wherein L is $–N(R^2)-$, W is alkyl, and R^2 is hydrogen or alkyl.


16. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of any one of claims 13-16, wherein the alkyl is a C_1-C_6 alkyl.

17. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of any one of the preceding claims, wherein Y is selected from the group consisting of alkyl, saturated

or unsaturated cycloalkyl, saturated or unsaturated heterocyclyl, -OC(O)OR^3, -OC(O)R^4, and –NR^{5}R^6, wherein said alkyl, saturated or unsaturated cycloalkyl, and saturated or unsaturated heterocyclyl are optionally substituted with one or more groups independently selected from oxo, halogen, cyano, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocyclyl, aryl, and heteroaryl.

18. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of any one of the preceding claims, wherein Y is unsaturated heterocyclyl, -OC(O)OR^3, -OC(O)R^4, and –NR^{5}R^6, wherein said unsaturated heterocyclyl is optionally substituted with one or more groups independently selected from oxo, halogen, cyano, alkyl, alkenyl, alkynyl, and heteroalkyl.

19. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of any one of the preceding claims, wherein Y is optionally substituted unsaturated 5- or 6-membered heterocyclyl having 1 or 2 oxygen atoms.

20. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of any one of the preceding claims, wherein Y is .

21. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of any one of claims 1-18, wherein Y is -OC(O)R^4.

22. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of claim 21, R^4 is C$_1$-C$_6$ alkyl.

23. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of claim 22, wherein the C$_1$-C$_6$ alkyl is methyl, ethyl, or isopropyl.

24. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of any one of


claims 1-18, wherein Y is $–NR^5R^6$.

25. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of claim 24, wherein R^5 is H or alkyl and R^6 is $-C(O)R^7$.


26. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of claim 25, wherein R^7 is C_1-C_6 alkyl or C_1-C_6 alkoxyl.

27. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of claim 26, wherein C_1-C_6 alkyl is $-CH_3$ or $-CH(CH_3)_2$ and C_1-C_6 alkoxyl $-OCH_3$ or $-OCH(CH_3)_2$.

28. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of claim 1, wherein the compound has a Formula (Ic-1) or Formula (Ic-2):




(Ic-1)




(Ic-2).

29. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of claim 1, wherein the compound has a Formula (Id-1) or Formula (Id-2):



(Id-1)



(Id-2).

30. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of claim 28 or 29, wherein R^{1b} is hydrogen.

31. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of claim 28 or 29, wherein R^{1b} is methyl.

32. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of any one of claims 28-31, wherein R^2 is H, alkyl, alkenyl or alkynyl.

33. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of any one of claims 28-31, wherein R^2 is H or C_1-C_6 alkyl.


34. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of any one of claims 28-33, wherein W is optionally substituted alkyl.

35. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of claim 34, wherein the optionally substituted alkyl is a C_1-C_6 alkyl.

36. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of claim 34, wherein the optionally substituted alkyl is a C_1-C_3 alkyl.

37. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of any one of claims 28-36, wherein Y is unsaturated heterocyclyl, $-OC(O)OR^3$, $-OC(O)R^4$, and $-NR^5R^6$, wherein said unsaturated heterocyclyl is optionally substituted with one or more groups independently selected from oxo, halogen, cyano, alkyl, alkenyl, alkynyl, and heteroalkyl.

38. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of any one of claims 28-37, wherein Y is optionally substituted unsaturated 5- or 6-membered heterocyclyl having 1 or 2 oxygen atoms.

39. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of any one of claims 28-38, wherein Y is .

40. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of any one of claims 28-36, wherein Y is $-OC(O)R^4$.

41. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of claim 40, R^4 is C_1-C_6 alkyl.

42. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of claim 41, wherein the C_1-C_6 alkyl is methyl, ethyl, or isopropyl.

43. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of any one of claims 28-36, wherein Y is $–NR^5R^6$.

44. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of claim 43, wherein R^5 is H or alkyl, and R^6 is $-C(O)R^7$.

45. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of claim 44, wherein R^7 is C_1-C_6 alkyl or C_1-C_6 alkoxyl.

46. The compound of Formula (I) or a pharmaceutically acceptable salt thereof, of claim 45, wherein C_1-C_6 alkyl is $-CH_3$ or $-CH(CH_3)_2$ and C_1-C_6 alkoxyl $-OCH_3$ or $-OCH(CH_3)_2$.

47. The compound of any one of preceding claims or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

[(3R,5S,8R,9S,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] hexanoate,

[(3R,5S,8R,9S,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] heptanoate,

(3R,5S,8R,9S,10S,13S,14S,17S)-17-acetyl-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl ocatanoate,

[(3R,5S,8R,9S,10S,13S,14S,17S)-17-acetyl-3,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl] hexanoate,

[(3R,5S,8R,9S,10S,13S,14S,17S)-17-acetyl-3,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl] heptanoate,

[(3R,5S,8R,9S,10S,13S,14S,17S)-17-acetyl-3,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl] octanoate,

[(3R,5S,8R,9S,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] 3-cyclopentylpropanoate,

[(3R,5S,8R,9S,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] 3-cyclopentylacetate,

[(3R,5S,8R,9S,10S,13S,14S,17S)-17-acetyl-3,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl] 3-cyclopentylpropanoate,

[(3R,5S,8R,9S,10S,13S,14S,17S)-17-acetyl-3,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl] 2-cyclopentylacetate,

[(3R,5S,8R,9S,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] 3-cyclopent-3-en-1-ylpropanoate,

[(3R,5S,8R,9S,10S,13S,14S,17S)-17-acetyl-3,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl] 3-cyclopent-3-en-1-ylpropanoate,

[(3R,5S,8R,9S,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] 3-(5-oxotetrahydrofuran-2-yl)propanoate,

[(3R,5S,8R,9S,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl]4-acetoxybutanoate,

[(3R,5S,8R,9S,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl]4-(2-methylpropanoyloxy)butanoate,

[(3R,5S,8R,9S,10S,13S,14S,17S)-17-acetyl- 10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] 5-acetoxyp entanoate,

[(3R,5S,8R,9S,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl]5-acetoxy-2-methyl-pentanoate,

3-[[(3R,5S,8R,9S,10S,13S,14S,17S)-17-acetyl-10,13- dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxycarbonyloxy]propyl acetate,

2-[[(3R,5S,8R,9S,10S,13S,14S,17S)- 17-acetyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxycarbonyloxy]ethyl 2-methylpropanoate,

[(3R,5S,8R,9S,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl](5-methyl-2-oxo-1,3-dioxol-4-yl)methyl carbonate,

[(3R,5S,8R,9S,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] butyl carbonate,

2-[[(3R,5S,8R,9S,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxycarbonylamino]ethyl 2-methylpropanoate,

2-[[(3R,5S,8R,9S,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxycarbonyl-methyl-amino]ethyl 2-methylpropanoate,

[(3R,5S,8R,9S,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] 2-(2-methyl propanoylamino)ethyl carbonate),

(3R,5S,8R,9S,10S,13S,14S,17S)-17-acetyl-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl(2-(N-methylisobutyramido)ethyl) carbonate,

[(3R,5S,8R,9S,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl]2-(methoxycarbonylamino)ethyl carbonate,

[(3R,5S,8R,9S,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl]2-(methoxycarbonyl-N-methyl amino)ethyl carbonate,

(3R,5S,8R,9S,10S,13S,14S,17S)-17-acetyl-3,10,13-trimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl ((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl) carbonate,

2-((((((3R,5S,8R,9S,10S,13S,14S,17S)-17-acetyl-3,10,13-trimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)carbonyl)(methyl)amino)ethyl isobutyrate,

2-(((((3R,5S,8R,9S,10S,13S,14S,17S)-17-acetyl-3,10,13-trimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)carbonyl)oxy)ethyl isobutyrate,

(3R,5R,8R,9R,10S,13S,14S,17S)-17-(2-(4-cyano-1H-pyrazol-1-yl)acetyl)-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl ((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl) carbonate,

2-((((((3R,5R,8R,9R,10S,13S,14S,17S)-17-(2-(4-cyano-1H-pyrazol-1-yl)acetyl)-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)carbonyl)(methyl)amino)ethyl isobutyrate, and

2-(((((3R,5R,8R,9R,10S,13S,14S,17S)-17-(2-(4-cyano-1H-pyrazol-1-yl)acetyl)-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)carbonyl)oxy)ethyl isobutyrate.

48. A pharmaceutical composition comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof, of any one of the preceding claims, and at least one pharmaceutically acceptable excipient.

49. A method of treating a disease or condition related to $GABA_A$ receptor function in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof, of any one of claims 1 to 47.

50. The method of claim 49, wherein the disease or condition is selected from the group consisting of a sleep disorder, a mood disorder, a dementia, a schizophrenia spectrum disorder, a convulsive disorder, an anxiety disorder, an autism spectrum disorder, a


disorder of memory and/or cognition, a movement disorder, a personality disorder, an autism spectrum disorder, pain, traumatic brain injury, a vascular disease, a substance abuse disorder, a withdrawal syndrome, and tinnitus.

51. The method of claim 50, wherein the sleep disorder is insomnia, the mood disorder is depression, the dementia is Alzheimer's type dementia, the convulsive disorder is epilepsy, and the movement disorder is Parkinson's disease.

52. The method of claim 49 or 50, wherein the disease is selected from the group consisting of CDD, MDD, PPD, essential tremor, PTSD, SE, ESE, Fragile X syndrome, Parkinson's Disease, or treatment resistant depression.

What is claimed is:


1. A compound of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein:

R^{1a} and R^{1b} each is independently hydrogen or methyl;

Q is methyl or  ;

L is selected from the group consisting of null, alkyl, -O-, and $–N(R^2)$-;

W is selected from the group consisting of null, alkyl, and –O-;

Y is selected from the group consisting of alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocyclyl, aryl, heteroaryl, $-OC(O)OR^3$, $-OC(O)R^4$, and $-NR^5R^6$, wherein said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocyclyl, aryl, and heteroaryl are optionally substituted with one or more groups independently selected from oxo, halogen, cyano, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocyclyl, aryl, and heteroaryl;

R^2, R^3, R^4 and R^5 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocyclyl, aryl, and heteroaryl, wherein said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocyclyl, aryl, and heteroaryl are optionally substituted with one or more groups independently selected from oxo, halogen, cyano, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocyclyl, aryl, and heteroaryl;

R^6 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, and -C(O)R^7; and

R^7 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, alkoxyl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocyclyl, aryl, and heteroaryl, wherein said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, alkoxyl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocyclyl, aryl, and heteroaryl are optionally substituted with one or more groups independently selected from oxo, halogen, cyano, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocyclyl, aryl, and heteroaryl,


with the provisos that when L is -O- or -N(R^2)-, W is not -O-, when W is -O-, Y is not -NR^5NR^6, and when W is -O-, Y is -C(O)OR^3 or -C(O)R^4.

2. The compound of claim 1, wherein R^{1a} and R^{1b} both are hydrogen.

3. The compound of claim 1, wherein R^{1a} and R^{1b} both are methyl.

4. The compound of claim 1, wherein R^{1a} is methyl and R^{1b} is hydrogen, or R^{1a} is hydrogen and R^{1b} is methyl.

5. The compound of any one of claims 1-4, wherein Q is methyl.

6. The compound of any one of claims 1-4, wherein Q is 

.

7. The compound of any one of claims 1-6, wherein L is –O-.

8. The compound of any one of claims 1-6, wherein L is –N(R^2)-, and R^2 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, and heteroalkynyl.

9. The compound of any one of claims 1-6, wherein L is $–N(R^2)-$, and R^2 is hydrogen or alkyl.

10. The compound of claim 8 or 9, wherein the alkyl is C_1-C_6 alkyl.

11. The compound of claim 8 or 9, wherein the alkyl is methyl.

12. The compound of any one of claims 1-11, wherein when L is null or alkyl, W is –O-.

13. The compound of any one of claims 1-6, wherein L is -O- and W is alkyl.

14. The compound of any one of claims 1-6, wherein L is $–N(R^2)-$, W is alkyl, and R^2 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, and heteroalkynyl.


15. The compound of any one of claims 1-6, wherein L is $–N(R^2)-$, W is alkyl, and R^2 is hydrogen or alkyl.

16. The compound of any one of claims 13-16, wherein the alkyl is a C_1-C_6 alkyl.

17. The compound of any one of claims 1-16, wherein Y is selected from the group consisting of alkyl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocyclyl, $-OC(O)OR^3$, $-OC(O)R^4$, and $–NR^5R^6$, wherein said alkyl, saturated or unsaturated cycloalkyl, and saturated or unsaturated heterocyclyl are optionally substituted with one or more groups independently selected from oxo, halogen, cyano, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, saturated or unsaturated cycloalkyl, saturated or unsaturated heterocyclyl, aryl, and heteroaryl.

18. The compound of any one of claims 1-17, wherein Y is unsaturated heterocyclyl, $-OC(O)OR^3$, $-OC(O)R^4$, and $–NR^5R^6$, wherein said unsaturated heterocyclyl is optionally substituted with one or more groups independently selected from oxo, halogen, cyano, alkyl, alkenyl, alkynyl, and heteroalkyl.

19. The compound of any one of claims 1-18, wherein Y is optionally substituted unsaturated 5- or 6-membered heterocyclyl having 1 to 3 oxygen atoms.

20. The compound of any one of claims 1-19, wherein Y is .

21. The compound of any one of claims 1-18, wherein Y is $-OC(O)R^4$.

22. The compound of claim 21, R^4 is C_1-C_6 alkyl.

23. The compound of claim 22, wherein the C_1-C_6 alkyl is methyl, ethyl, or isopropyl.


24. The compound of any one of claims 1-18, wherein Y is $–NR^5R^6$.

25. The compound of claim 24, wherein R^5 is H or alkyl and R^6 is $-C(O)R^7$.


26. The compound of claim 25, wherein R^7 is C_1-C_6 alkyl or C_1-C_6 alkoxyl.

27. The compound of claim 26, wherein the C_1-C_6 alkyl is $-CH_3$ or $-CH(CH_3)_2$ and the C_1-C_6 alkoxyl $-OCH_3$ or $-OCH(CH_3)_2$.

28. The compound of claim 1, wherein the compound has a structure of Formula (Ic-1) or Formula (Ic-2):




(Ic-1)




(Ic-2).

29. The compound of claim 1, wherein the compound has a structure of Formula (Id-1) or

Formula (Id-2):



(Id-1)



(Id-2).

30. The compound of claim 28 or 29, wherein R^{1b} is hydrogen.

31. The compound of claim 28 or 29, wherein R^{1b} is methyl.

32. The compound of any one of claims 28-31, wherein R^2 is H, alkyl, alkenyl or alkynyl.

33. The compound of any one of claims 28-31, wherein R^2 is H or C_1-C_6 alkyl.


34. The compound of any one of claims 28-33, wherein W is optionally substituted alkyl.

35. The compound of claim 34, wherein the optionally substituted alkyl is a C_1-C_6 alkyl.

36. The compound of claim 34, wherein the optionally substituted alkyl is a C_1-C_3 alkyl.

37. The compound of any one of claims 28-36, wherein Y is unsaturated heterocyclyl, -$OC(O)OR^3$, -$OC(O)R^4$, and –NR^5R^6, wherein said unsaturated heterocyclyl is optionally substituted with one or more groups independently selected from oxo, halogen, cyano, alkyl, alkenyl, alkynyl, and heteroalkyl.

38. The compound of any one of claims 28-37, wherein Y is optionally substituted unsaturated 5- or 6-membered heterocyclyl having 1 to 3 oxygen atoms.

39. The compound of any one of claims 28-38, wherein Y is .

40. The compound of any one of claims 28-36, wherein Y is -OC(O)R^4.

41. The compound of claim 37 or 40, wherein R^4 is C_1-C_6 alkyl.

42. The compound of claim 41, wherein the C_1-C_6 alkyl is methyl, ethyl, or isopropyl.


43. The compound of any one of claims 28-36, wherein Y is –NR^5R^6.


44. The compound of claim 43, wherein R^5 is H or alkyl, and R^6 is -C(O)R^7.













45. The compound of claim 44, wherein R^7 is C_1-C_6 alkyl or C_1-C_6 alkoxyl.











46. The compound of claim 45, wherein the C_1-C_6 alkyl is -CH_3 or -$CH(CH_3)_2$ and the C_1-C_6 alkoxyl -OCH_3 or -$OCH(CH_3)_2$.


47. The compound of any one of claims 1-46, wherein the compound is selected from the group consisting of:


,


,


 ,	 ,
 ,	 ,
 ,	 ,
 ,	 ,
 ,	 ,
 ,	 ,


 ,	 ,
 ,	 ,
 ,	 ,
 ,	 ,
 ,	 ,



,



,



,



,


,


,


,


, and


.

48. A pharmaceutical composition comprising a compound of Formula (I) of any one of claims 1-47, and at least one pharmaceutically acceptable excipient.

49. Use of the compound of any one of claims 1 to 47 or the pharmaceutical composition of

claim 48 in the manufacture of a medicament for the treatment of a disease or condition related to $GABA_A$ receptor function in a subject, wherein the disease or condition is selected from the group consisting of a sleep disorder, a mood disorder, a dementia, a schizophrenia spectrum disorder, a convulsive disorder, an anxiety disorder, an autism spectrum disorder, a disorder of memory and/or cognition, a movement disorder, a personality disorder, an autism spectrum disorder, pain, traumatic brain injury, a vascular disease, a substance abuse disorder, a withdrawal syndrome, and tinnitus.

50. The use of claim 49, wherein the sleep disorder is insomnia, the mood disorder is depression, the dementia is Alzheimer's type dementia, the convulsive disorder is epilepsy, and the movement disorder is Parkinson's disease.

51. The use of claim 49, wherein the disease is selected from the group consisting of CDKL5 deficiency disorder (CDD), major depressive disorder (MDD), postpartum depression (PPD), essential tremor, post-traumatic stress disorder (PTSD), status epilepticus (SE), electrographic status epilepticus (ESE), Fragile X syndrome, Parkinson's Disease, or treatment resistant depression.

52. The compound of any one of claims 1-47 or the pharmaceutical composition of claim 48 for use in therapy.